RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
This study is testing a new targeted cancer medicine called daraxonrasib against standard chemotherapy for people with advanced pancreatic cancer. Researchers want to see if this new approach works better and is safer than current treatments.
You may be able to join if you are 18 or older, have pancreatic cancer that has spread to other parts of the body, and have already tried previous treatments. Your general health and organ functions must also meet specific requirements to ensure you can safely take part.
Participants will be randomly assigned to receive either the new study drug or a standard chemotherapy chosen by your doctor. You will have regular clinic visits, health checks, and scans so the medical team can monitor your safety and how your tumor responds.
The study has locations in Arizona and California, though it is currently active and not actively looking for new patients. Your care team can help you find out if other similar options are available.
- 1Tests a new targeted cancer drug versus standard chemotherapy.
- 2For adults with previously treated, advanced pancreatic cancer.
- 3Currently active but not open for new participant enrollment.
Related videos
3Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.